Summit notes Akeso reported OS benefit in HARMONi-2
Summit Therapeutics said partner Akeso reported ivonescimab achieved a statistically significant overall survival benefit versus pembrolizumab in the Phase III HARMONi-2 study.
Summit Therapeutics noted partner Akeso reported ivonescimab achieved a statistically significant overall survival benefit vs pembrolizumab in the Phase III HARMONi-2 study.Key Highlights:Original SEC Filing: Summit Therapeutics Inc. [ SMMT ] - 8-K - Sep.
03, 2026This is an AI-powered summary.
It m…